Archer Materials (ASX: AXE) has achieved a significant milestone with its Biochip technology, unveiling an alpha prototype of a potassium sensor that meets clinical-grade accuracy standards. This development aligns with the company's roadmap towards a beta prototype in 2026, positioning it to pursue licensing discussions with MedTech partners. Biochip Prototype Hits Clinical AccuracyArcher has delivered an alpha prototype of its integrated Biochip-based potassium sensor. Path to Beta Prototype and PartnershipsThis alpha prototype is a crucial step towards the planned beta prototype. Outlook for Biochip and QuantumArcher Materials has demonstrated significant progress with its Biochip prototype, achieving critical accuracy milestones that pave the way for future commercial partnerships.